KalVista Pharmaceuticals, Inc. provides an operational update and releases financial results for the second fiscal quarter ended 31 October 2022:
“We made a very difficult decision this quarter in terminating our phase 2 KOMPLETE trial for KVD824, but the safety of patients is of utmost importance to our Company,” says Andrew Crockett, CEO of KalVista. “We remain committed to providing best-in-class oral treatments for the HAE community. We are particularly excited about our recent data for the orally disintegrating tablet (ODT) formulation of sebetralstat, which will enable people to take a dose without requiring chewing or swallowing. We are also pleased with the progress of our Phase 3 KONFIDENT clinical trial for sebetralstat, which remains on our enrollment target for data in the second half of 2023.”
(Source: KalVista)
